The move from Ms. McCaskill follows the Oct. 15 publication of an investigative report conducted by The Washington Post and “60 Minutes.” The report details circumstances behind the passage of the Ensuring Patient Access and Effective Drug Enforcement Act, which effectively eliminated DEA’s ability to freeze suspicious shipments of opioids from drug distributors.
“Media reports indicate that this law has significantly affected the government’s ability to crack down on opioid distributors that are failing to meet their obligations and endangering our communities,” said Ms. McCaskill. “I’ll be introducing legislation that repeals this law and continue my work investigating the role pharmaceutical distributors played in fueling this public health crisis.”
The Democratic Senator launched a formal investigation into drug companies’ possible role in facilitating opioid overprescribing in March.
More articles on opioids:
Murkowski-Warren letter urges Trump to move on opioid crisis emergency declaration
Congress weakened DEA’s power to investigate drug distributors at height of opioid epidemic: 7 things to know
10 recent opioid epidemic lawsuits
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
